ResMed Q4 revenue up 9% to $1.5B; non-GAAP EPS $2.95 (+16%); dividend raised 10%

RESMED INC

Q4 revenue $1.464B (+9% YoY); GAAP EPS $2.64 (+2%); non-GAAP EPS $2.95 (+16%).
FY2026 revenue $5.653B (+10%); GAAP EPS $10.43; non-GAAP EPS $11.17 (+17%).
FY2026 free cash flow $1.6B; returned $1.0B to shareholders; FY2027 capital return guided >$1.85B.
Dividend increased 10% to $0.66/quarter; record date Aug 20, payable Sep 24.
Agreement to sell MatrixCare (close Q1 FY2027); completed acquisition of Noctrix Health.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.